BioMarin Pharmaceutical Inc. and Prosensa Holding N.V. announced that they have entered into a definitive agreement in which BioMarin will offer to purchase all of the outstanding ordinary shares of Prosensa for $17.75 per share, for a total up front consideration of approximately $680 million. In addition, two approximately $80 million contingent milestones are payable for the approval of drisapersen in the U.S. no later than May 15, 2016 and Europe no later than February 15, 2017, respectively.
Galapagos NV, a clinical stage biotech company focused on developing novel mode of action medicines, announces that recruitment of rheumatoid arthritis (RA) patients for the Darwin 2 study with GLPG0634 has been completed. The Darwin Phase 2B program is now fully recruited and will begin a series of topline readouts starting around end of the first quarter 2015.
Galapagos NV, a clinical stage biotech company focused on developing novel mode of action medicines, announces that it will present data supporting the safe use and absence of drug-drug interactions of GLPG0634 (filgotinib) with drugs commonly prescribed for rheumatoid arthritis (RA) patients. In addition, Galapagos will show support for the dose selection in the Phase 2B DARWIN program and present the reversals of RA disease gene expression in patients treated with GLPG0634.
Galapagos NV, a clinical stage biotech company focused on developing novel mode of action medicines, announces that GSK has disclosed on its website the Phase 2 psoriasis study results with selective JAK1inhibitor GSK2856184, licensed from Galapagos. The results show higher efficacy than those published for apremilast, a recently approved oral medicine for psoriasis and psoriatic arthritis.
As of November, Dutch Space, supplier of high tech products and services for the international aerospace industry, will be known under the name of Airbus Defence and Space Netherlands B.V. The change of name of the Dutch company, which plays a leading role in space since the late sixties, stems from the rebranding of the parent company early this year. The new company name, which will be visible today with the new corporate identity and the launch of the website www.airbusDS.nl, has no further effect on the Leiden based organization and its employees.
Pharming and Salix announce the launch of Ruconest® in the U.S. for the treatment of acute angioedema attacks in patients with Hereditary Angioedema (HAE)Published : Monday, November 3, 2014
Pharming Group NV and Salix Pharmaceuticals, Ltd. announced the launch of RUCONEST® (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg in the United States for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE). Effectiveness in clinical studies was not established in HAE patients with laryngeal attacks. This announcement follows the July approval of the drug by the Food and Drug Administration.
Condi food has won the Herman Wijffels Innovation Award 2014 in the category Agri & Food. There were more than 600 subscription in 3 categories. Condi food is a joint venture of cosine measurement systems and Jan Rolloos Ventures, and develops and supplies advanced camera inspection systems for the food industry.
The advent of DNA barcoding techniques speeded up the identification and characterization of new species and yielded many new insights. However, these techniques are not always applicable. For example, in most fossils DNA is not present and the Jurrasic Park techniques to dinosaur blood from a mosquito trapped in amber, still remains wishful thinking.
>Read more in Dutch
SkylineDx, an innovative company in the field of genetic testing for blood cancers, announced a strategic investment of an undisclosed sum in the Dutch cancer vaccine company DCPrime. The financing is designed to provide DCPrime with funding for the development of its technology platform and to take advantage of the synergies between the cancer companies.
Galapagos and Calchan collaborate on osteoarthritis research, £2.4 million grant awarded by Innovate UKPublished : Monday, October 27, 2014
Galapagos NV, a clinical stage biotech company focused on developing novel mode of action medicines, and Calchan Limited, a UK company focused on the development of novel medicines based on calcium ion channel modulators, announced that they have entered into a research collaboration in the area of osteoarthritis pain.
Leiden Bio Science Park foundation was present at the LUMC Science Day at October 26th. The very popular open day consists of a large fair with LUMC departments, all kind of tests and lectures.
Leiden Bio Science Park foundation organised 4 lectures that accompanied the viewing of the Red carpet (Rode Loper) films about the chain of drug development at Leiden Bio Science Park.
Beginning of October Thijs de Kleer, director and Ellen Smit, senior account manager, both of the Leiden Bio Science Park foundation visited Japan. During this trip, they visited life sciences companies including AnGes, Daiichi Sankyo and Maruho. A small seminar was organized by the Osaka Pharmaceutical Manufacturers Association where Leiden Bio Science Park was presented to life science companies in Osaka.
Galapagos discloses GPR84 as a promising novel target for treating inflammatory bowel disease during an oral presentation at United European Gastroenterology Week in Vienna on 21 October. Furthermore, Galapagos presents a poster disclosing favorable Phase 1 results with GLPG1205, the first clinical compound ever developed against target GPR84.
The Leiden Bio Science Park newsletter is a free bimonthly email newsletter in English. The newsletter offers general life science news, news from the companies and institutions, a company profile, events and jobs.
click here to subscribe